The chart below shows how HLN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HLN sees a -1.70% change in stock price 10 days leading up to the earnings, and a -0.19% change 10 days following the report. On the earnings day itself, the stock moves by +0.54%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Organic Revenue Performance: Organic revenue growth was 6.1%, with Power Brands growing 5.4% and emerging markets delivering 11% growth, particularly in China.
Organic Profit Growth Rates: Organic profit growth was 7.4% for the quarter, leading to 9.7% organic profit growth for the first nine months of the year.
Share Buyback Allocation: Haleon completed a £500 million share buyback allocation for the year, returning over £1 billion of capital to shareholders in 2024.
Bond Issuance Success: The company raised around £900 million in bonds at attractive rates, demonstrating strong demand and financial stability.
Stake Increase in China Joint Venture: Haleon announced an agreement to increase its stake in the China joint venture by 33%, enhancing its position in a key growth market.
Negative
M&A Impact on Revenue: Net M&A represented a headwind to reported revenue of 1.8%, due to the disposals of Lamisil and ChapStick, negatively impacting overall revenue performance.
Foreign Exchange Impact on Revenue: Foreign exchange had a significant adverse impact on reported revenue, reducing it by 4.9%, which was exacerbated by the strength of sterling against the U.S. dollar and other emerging market currencies.
Revenue Decline Despite Growth: Reported revenue declined 0.6% in the quarter, indicating a negative trend despite a 6.1% organic growth, highlighting challenges in overall revenue generation.
Operating Profit Decline: Operating profit saw a 7.2% decline, resulting in a 23% margin for the quarter, which reflects a significant drop in profitability despite organic profit growth.
Foreign Exchange Impact Analysis: The company faced a £69 million adverse impact from translational foreign exchange, which was a greater proportionate impact than the revenue decline, indicating operational vulnerabilities.